By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina today reported preliminary first-quarter revenues of $270 million, down more than 4 percent compared to the first quarter of 2011 but above Wall Street's consensus estimate of $257.4 million.

The company, which plans to formally report first-quarter results later this month, added that it expects non-GAAP earnings per share for the first quarter to be "at or above current consensus estimates."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.